FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4241450237> ?p ?o ?g. }

• W4241450237 endingPage "208" @default.
• W4241450237 startingPage "208" @default.
• W4241450237 abstract "208 Background: Testosterone replacement therapy (TRT) in patients previously treated for prostate cancer is controversial. We analyzed biochemical relapse and sexual function in patients treated for prostate cancer with proton therapy (PT) at our institution who were later treated with TRT for hypogonadism. Methods: We reviewed the medical records of 27 patients with biopsy-proven, localized prostate cancer treated with definitive proton therapy (PT) at our institution between 2006 and 2012. Each patient had hypogondal symptoms and low-serum testosterone and received testosterone replacement after PT. Biochemical failure was defined by the Phoenix definition. Sexual function was reported using patient-reported data from the Expanded Prostate Cancer Index Composite (EPIC) questionnaire. Rates of sexual potency were also reported. Results: Twenty-three patients were included in the present analysis. The median follow-up duration was 38 months after PT and 14 months after initiation of TRT. After one to six months on TRT, the median serum testosterone level in this patient cohort increased from 238 to 497. No patient experienced a biochemical failure. The median prostate-specific antigen (PSA) did not significantly rise during the follow-up period. EPIC sexual summary, sexual function, and sexual bother scores all increased after initiation of TRT. The median sexual bother scores increased from 43.8 before TRT to 59.4 after 7 or more months of TRT. The median sexual summary scores improved from 50 to 61.8 and the median sexual function scores improved from 41.7 to 53 over the same time. Sexual potency also increased after TRT initiation from 50% to 68%, 7 or more months after TRT. Conclusions: For patients diagnosed with hypogonadism who were previously treated for prostate cancer, cautious use of testosterone replacement therapy does not appear to increase the risk of biochemical failure or increase PSA. Sexual function may improve to approximate pre-radiation levels in some cases. A prospective trial with long-term follow up is required to better support our findings." @default.
• W4241450237 created "2022-05-12" @default.
• W4241450237 creator A5005329877 @default.
• W4241450237 creator A5008642709 @default.
• W4241450237 creator A5023899503 @default.
• W4241450237 creator A5040103581 @default.
• W4241450237 creator A5042972157 @default.
• W4241450237 creator A5053264588 @default.
• W4241450237 creator A5058130022 @default.
• W4241450237 creator A5065815535 @default.
• W4241450237 creator A5071374686 @default.
• W4241450237 creator A5078705257 @default.
• W4241450237 date "2014-02-01" @default.
• W4241450237 modified "2023-09-26" @default.
• W4241450237 title "Testosterone replacement therapy in men with prostate cancer after proton therapy." @default.
• W4241450237 doi "https://doi.org/10.1200/jco.2014.32.4_suppl.208" @default.
• W4241450237 hasPublicationYear "2014" @default.
• W4241450237 type Work @default.
• W4241450237 citedByCount "0" @default.
• W4241450237 crossrefType "journal-article" @default.
• W4241450237 hasAuthorship W4241450237A5005329877 @default.
• W4241450237 hasAuthorship W4241450237A5008642709 @default.
• W4241450237 hasAuthorship W4241450237A5023899503 @default.
• W4241450237 hasAuthorship W4241450237A5040103581 @default.
• W4241450237 hasAuthorship W4241450237A5042972157 @default.
• W4241450237 hasAuthorship W4241450237A5053264588 @default.
• W4241450237 hasAuthorship W4241450237A5058130022 @default.
• W4241450237 hasAuthorship W4241450237A5065815535 @default.
• W4241450237 hasAuthorship W4241450237A5071374686 @default.
• W4241450237 hasAuthorship W4241450237A5078705257 @default.
• W4241450237 hasConcept C121608353 @default.
• W4241450237 hasConcept C126322002 @default.
• W4241450237 hasConcept C126894567 @default.
• W4241450237 hasConcept C2775871022 @default.
• W4241450237 hasConcept C2776235491 @default.
• W4241450237 hasConcept C2777899217 @default.
• W4241450237 hasConcept C2779279991 @default.
• W4241450237 hasConcept C2780192828 @default.
• W4241450237 hasConcept C29456083 @default.
• W4241450237 hasConcept C71924100 @default.
• W4241450237 hasConceptScore W4241450237C121608353 @default.
• W4241450237 hasConceptScore W4241450237C126322002 @default.
• W4241450237 hasConceptScore W4241450237C126894567 @default.
• W4241450237 hasConceptScore W4241450237C2775871022 @default.
• W4241450237 hasConceptScore W4241450237C2776235491 @default.
• W4241450237 hasConceptScore W4241450237C2777899217 @default.
• W4241450237 hasConceptScore W4241450237C2779279991 @default.
• W4241450237 hasConceptScore W4241450237C2780192828 @default.
• W4241450237 hasConceptScore W4241450237C29456083 @default.
• W4241450237 hasConceptScore W4241450237C71924100 @default.
• W4241450237 hasIssue "4_suppl" @default.
• W4241450237 hasLocation W42414502371 @default.
• W4241450237 hasOpenAccess W4241450237 @default.
• W4241450237 hasPrimaryLocation W42414502371 @default.
• W4241450237 hasRelatedWork W1982508997 @default.
• W4241450237 hasRelatedWork W2127440557 @default.
• W4241450237 hasRelatedWork W2150609534 @default.
• W4241450237 hasRelatedWork W2909802736 @default.
• W4241450237 hasRelatedWork W2969214722 @default.
• W4241450237 hasRelatedWork W3030606693 @default.
• W4241450237 hasRelatedWork W4286561766 @default.
• W4241450237 hasRelatedWork W4295897810 @default.
• W4241450237 hasRelatedWork W4308148977 @default.
• W4241450237 hasRelatedWork W83392053 @default.
• W4241450237 hasVolume "32" @default.
• W4241450237 isParatext "false" @default.
• W4241450237 isRetracted "false" @default.
• W4241450237 workType "article" @default.